REMEDY Act
S. 2620
This bill limits the scope of a 30-month stay on approval of a generic drug by the Food and Drug Administration (FDA) while patent litigation involving the reference (brand-name) drug is ongoing.
Learn about this bill’s status and read its full summary in the Pocket Congress app.
Open in the Pocket Congress app 
Scan to open this page in Pocket Congress